News Release

McGlinchey’s Rasch Brown Named Among Lawdragon’s 500 Leading U.S. Litigators for 2025

October 7, 2024

McGlinchey is proud to announce that Member (Partner) Francis “Rasch” H. Brown, III has been named to Lawdragon’s 2025 list of 500 Leading Litigators in America in the areas of commercial liability, products liability, and torts.

The Lawdragon honorees are attorneys who excel at representing corporations and other organizations in litigating claims involving antitrust, securities, financial, M&A, intellectual property and patents, product liability, mass tort, white collar, government investigations, and energy disputes.

“I am honored to receive this recognition for the third consecutive year,” said Rasch. “Each acknowledgment affirms my commitment to guiding clients through complex litigation with practical and strategic solutions. It’s a privilege to continue serving clients nationwide in such a critical area of law.”

Rasch is an experienced trial lawyer who advises clients throughout the country on tort litigation and commercial disputes, with an emphasis on products liability defense. Based in New Orleans and Houston, he has tried many products liability cases to conclusion, obtaining defense verdicts in Alabama, Florida, Georgia, Louisiana, Mississippi, South Carolina, and Texas. He is a Fellow of the American College of Trial Lawyers and a Martindale-Hubbell AV^® Preeminent™ Rated Lawyer. He was honored with the New Orleans CityBusiness Leadership in Law award in 2019 and has been named among The Best Lawyers in America^® for product liability litigation for defendants since 2021.

Lawdragon is a legal media company that provides free online news and editorial features, including guides to the nation’s leading lawyers, as well as content, marketing, and branding services for lawyers and law firms. The Leading Litigators in America list is compiled through submissions and independent research focused on recent cases and defense verdicts or settlements, as well as attorneys whose sustained excellence in trials is deemed “nothing short of remarkable.”